Update: Opus Genetics Shares Rise After Reporting Vision Improvement in Phase 1/2 OPGx-BEST1 Trial

02:35 PM EDT, 09/09/2026 (MT Newswires) -- (Updates to add share movement in first paragraph and headline) Opus Genetics (IRD) shares jumped 30% in Wednesday trading after it said that patients with Bestrophin-1-related retinal diseases showed clinically meaningful improvement in visual function in the low-dose cohort 1 of its BIRD-1 phase 1/2 clinical trial evaluating OPGx-BEST1. The biopharmaceutical company said the five participants in the trial with BEST1-related retinal diseases showed meaningful visual improvements. It also said four of the five patients showed structural improvements. There were no serious adverse events, dose-limiting toxicities, or intraocular inflammation reported in the trial. Price: 5.79, Change: +1.45, Percent Change: +33.29